Talomune 0.5 Mg/ 1 Mg/ 5 Mg 0.5mg/ 1mg/ 5mg Capsule
PDF Leaflet Revision Date: 22 February 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Primary immunosuppression in organ transplant recipients.
Dosage (summary)
Initial oral dose: 0.10-0.40 mg/kg/day in two divided doses.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
- Paediatric patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Ciclosporin
- Grapefruit juice
Contraindications
- Hypersensitivity to tacrolimus
- Pregnancy
- Lactation
- Live vaccines
- Ciclosporin
Common side effects
- Increased risk of infections
- Nephrotoxicity
- Hypertension
- Hyperglycaemia
Counselling Points
- Take on an empty stomach
- Monitor blood glucose
- Avoid grapefruit juice
- Report signs of infection
Serious warnings
- Increased risk of malignancies
- Medication errors with tacrolimus formulations
- Serious infections
Important Disclaimer
The Talomune 0.5 Mg/ 1 Mg/ 5 Mg 0.5mg/ 1mg/ 5mg Capsule professional information leaflet below is the property of Strides Pharma Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
